Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: Pooled data from 9 short-term, double-blind, placebo-controlled trials

CNS Spectrums

Volumn 15, Issue 3, 2010, Pages 187-193

  Tourian, Karen A ^a   Jiang, Qin ^a   Ninan, Philip T ^a  

^a a company of the Pfizer Group   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE;

ANALYSIS OF COVARIANCE; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; PRIORITY JOURNAL; SCORING SYSTEM; SOMATIZATION; ADULT; ANXIETY; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; OUTPATIENT; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANXIETY; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77952303668     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900027450     Document Type: Article

References (37)

1. Fawcett J, Clark DC, Scheftner WA, Gibbons RD. Assessing anhedonia in psychiatric patients. Arch Gen Psychiatry. 1983;40:79-84.
2. Fava M, Alpert JE, Carmin CN, et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004;34:1299-1308.
3. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. Am J Psychiatry. 2008;165:342-351.
4. Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:4-13.
5. Joffe RT, Bagby RM, Levitt A. Anxious and nonanxious depression. Am J Psychiatry. 1993;150:1257-1258.
6. Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55:50-59.
7. Nelson JC. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depress Anxiety. 2010;27:12-18.
8. Keller MB, Krystal JH, Hen R, Neumeister A, Simon NM. Untangling depression and anxiety: clinical challenges. J Clin Psychiatry. 2005;66:1477-1484.
9. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765.
10. Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J Clin Psychiatry. 2006;67:600-610.
11. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007;194:233-242.
12. Katon WJ. Clinical practice. Panic disorder. N Engl J Med. 2006;354:2360-2367.
13. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry. 2006;67(suppl 12):20-26.
14. Fricchione G. Clinical practice. Generalized anxiety disorder. N Engl J Med. 2004;351:675-682.
15. Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 19):11-19.
16. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord. 1998;47:55-62.
17. Nutt DJ. Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60(suppl 17):23-27.
18. Papakostas GI, Trivedi MH, Alpert JE, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. J Psychiatr Res. 2008;42:134-140.
19. Deecher DC, Beyer CE, Johnston G et al. Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318:657-665.
20. Desvenlafaxine [package insert]. Collegeville, PA: Wyeth Pharmaceuticals; 2008.
21. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain J-M, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22:338-347.
22. DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68:677-688.
23. Liebowitz M, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68:1663-1672.
24. Liebowitz M, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24:1877-1890.
25. Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23:243-253.
26. Rudolph RL, Entsuah R, Chitra R. A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol. 1998;18:136-144.
27. Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18:53-61.
28. Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25:182-189.
29. Lieberman DZ, Montgomery SA, Tourian KA et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23:188-197.
30. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association; 1994.
31. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
32. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
33. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
34. Lipman RS. Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull. 1982;18:69-77.
35. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ. Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis. 1969;148:87-98.
36. Thase ME, Kornstein SG, Germain J-M, Jiang Q, Guico-Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009;14:144-154.
37. Thase ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull. 2002;36(suppl 1):1-17.